According to an FDA recall notice, issued today, the action affects 13,440 devices in the United States.

Even in these largely “stable” statin takers, less adherence tracked with higher mortality in a dose-response fashion.

The extent of cardiac damage at baseline strongly correlated with both post-TAVR mortality and the risk of cardiac and noncardiac readmissions.

The prematurely halted EXTEND trial suggests benefits can be seen in patients who present within 9 hours or who wake up with a stroke.

Post hoc analysis of the IRIS trial suggests that it should.

The ability to identify female patients with angina but without CAD will take simpler invasive protocols and noninvasive tools.

The reversal agent for the factor Xa inhibitors has recently been added to the US A-fib guidelines.

The study is the latest response to concerns of excess mortality that were raised by a summary-level meta-analysis published late last year.

The CSPS.com trial has limitations but raises questions about whether more patients will benefit from dual antiplatelet therapy.

“Once you start paying attention to a problem, then it’s easier to find solutions,” one conference leader says.

This problem is too big to ignore any longer, say investigators, who point out that the vast majority of people under financial strain are insured.